Global Viibryd (Vilazodone) Market Growth 2025-2031

December 2025 | 85 pages | ID: G6EAF21097F8EN
LP Information

Abstracts

The global Viibryd (Vilazodone) market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

United States market for Viibryd (Vilazodone) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Viibryd (Vilazodone) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Viibryd (Vilazodone) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Viibryd (Vilazodone) players cover Allergan plc (AbbVie Inc.), Actavis Generics (Teva), Clinical Data, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Viibryd (Vilazodone) Industry Forecast” looks at past sales and reviews total world Viibryd (Vilazodone) sales in 2024, providing a comprehensive analysis by region and market sector of projected Viibryd (Vilazodone) sales for 2025 through 2031. With Viibryd (Vilazodone) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viibryd (Vilazodone) industry.

This Insight Report provides a comprehensive analysis of the global Viibryd (Vilazodone) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Viibryd (Vilazodone) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viibryd (Vilazodone) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viibryd (Vilazodone) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viibryd (Vilazodone).

This report presents a comprehensive overview, market shares, and growth opportunities of Viibryd (Vilazodone) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• 10 mg
• 20 mg
• 40 mg

Segmentation by Application:

• Major Depression
• Anxiety
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Allergan plc (AbbVie Inc.)
• Actavis Generics (Teva)
• Clinical Data, Inc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Viibryd (Vilazodone) market?

What factors are driving Viibryd (Vilazodone) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Viibryd (Vilazodone) market opportunities vary by end market size?

How does Viibryd (Vilazodone) break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Viibryd (Vilazodone) Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Viibryd (Vilazodone) by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Viibryd (Vilazodone) by Country/Region, 2020, 2024 & 2031
2.2 Viibryd (Vilazodone) Segment by Type
  2.2.1 10 mg
  2.2.2 20 mg
  2.2.3 40 mg
2.3 Viibryd (Vilazodone) Sales by Type
  2.3.1 Global Viibryd (Vilazodone) Sales Market Share by Type (2020-2025)
  2.3.2 Global Viibryd (Vilazodone) Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Viibryd (Vilazodone) Sale Price by Type (2020-2025)
2.4 Viibryd (Vilazodone) Segment by Application
  2.4.1 Major Depression
  2.4.2 Anxiety
  2.4.3 Others
2.5 Viibryd (Vilazodone) Sales by Application
  2.5.1 Global Viibryd (Vilazodone) Sale Market Share by Application (2020-2025)
  2.5.2 Global Viibryd (Vilazodone) Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Viibryd (Vilazodone) Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Viibryd (Vilazodone) Breakdown Data by Company
  3.1.1 Global Viibryd (Vilazodone) Annual Sales by Company (2020-2025)
  3.1.2 Global Viibryd (Vilazodone) Sales Market Share by Company (2020-2025)
3.2 Global Viibryd (Vilazodone) Annual Revenue by Company (2020-2025)
  3.2.1 Global Viibryd (Vilazodone) Revenue by Company (2020-2025)
  3.2.2 Global Viibryd (Vilazodone) Revenue Market Share by Company (2020-2025)
3.3 Global Viibryd (Vilazodone) Sale Price by Company
3.4 Key Manufacturers Viibryd (Vilazodone) Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Viibryd (Vilazodone) Product Location Distribution
  3.4.2 Players Viibryd (Vilazodone) Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR VIIBRYD (VILAZODONE) BY GEOGRAPHIC REGION

4.1 World Historic Viibryd (Vilazodone) Market Size by Geographic Region (2020-2025)
  4.1.1 Global Viibryd (Vilazodone) Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Viibryd (Vilazodone) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Viibryd (Vilazodone) Market Size by Country/Region (2020-2025)
  4.2.1 Global Viibryd (Vilazodone) Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Viibryd (Vilazodone) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Viibryd (Vilazodone) Sales Growth
4.4 APAC Viibryd (Vilazodone) Sales Growth
4.5 Europe Viibryd (Vilazodone) Sales Growth
4.6 Middle East & Africa Viibryd (Vilazodone) Sales Growth

5 AMERICAS

5.1 Americas Viibryd (Vilazodone) Sales by Country
  5.1.1 Americas Viibryd (Vilazodone) Sales by Country (2020-2025)
  5.1.2 Americas Viibryd (Vilazodone) Revenue by Country (2020-2025)
5.2 Americas Viibryd (Vilazodone) Sales by Type (2020-2025)
5.3 Americas Viibryd (Vilazodone) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Viibryd (Vilazodone) Sales by Region
  6.1.1 APAC Viibryd (Vilazodone) Sales by Region (2020-2025)
  6.1.2 APAC Viibryd (Vilazodone) Revenue by Region (2020-2025)
6.2 APAC Viibryd (Vilazodone) Sales by Type (2020-2025)
6.3 APAC Viibryd (Vilazodone) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Viibryd (Vilazodone) by Country
  7.1.1 Europe Viibryd (Vilazodone) Sales by Country (2020-2025)
  7.1.2 Europe Viibryd (Vilazodone) Revenue by Country (2020-2025)
7.2 Europe Viibryd (Vilazodone) Sales by Type (2020-2025)
7.3 Europe Viibryd (Vilazodone) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Viibryd (Vilazodone) by Country
  8.1.1 Middle East & Africa Viibryd (Vilazodone) Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Viibryd (Vilazodone) Revenue by Country (2020-2025)
8.2 Middle East & Africa Viibryd (Vilazodone) Sales by Type (2020-2025)
8.3 Middle East & Africa Viibryd (Vilazodone) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Viibryd (Vilazodone)
10.3 Manufacturing Process Analysis of Viibryd (Vilazodone)
10.4 Industry Chain Structure of Viibryd (Vilazodone)

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Viibryd (Vilazodone) Distributors
11.3 Viibryd (Vilazodone) Customer

12 WORLD FORECAST REVIEW FOR VIIBRYD (VILAZODONE) BY GEOGRAPHIC REGION

12.1 Global Viibryd (Vilazodone) Market Size Forecast by Region
  12.1.1 Global Viibryd (Vilazodone) Forecast by Region (2026-2031)
  12.1.2 Global Viibryd (Vilazodone) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Viibryd (Vilazodone) Forecast by Type (2026-2031)
12.7 Global Viibryd (Vilazodone) Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Allergan plc (AbbVie Inc.)
  13.1.1 Allergan plc (AbbVie Inc.) Company Information
  13.1.2 Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Product Portfolios and Specifications
  13.1.3 Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Allergan plc (AbbVie Inc.) Main Business Overview
  13.1.5 Allergan plc (AbbVie Inc.) Latest Developments
13.2 Actavis Generics (Teva)
  13.2.1 Actavis Generics (Teva) Company Information
  13.2.2 Actavis Generics (Teva) Viibryd (Vilazodone) Product Portfolios and Specifications
  13.2.3 Actavis Generics (Teva) Viibryd (Vilazodone) Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Actavis Generics (Teva) Main Business Overview
  13.2.5 Actavis Generics (Teva) Latest Developments
13.3 Clinical Data, Inc.
  13.3.1 Clinical Data, Inc. Company Information
  13.3.2 Clinical Data, Inc. Viibryd (Vilazodone) Product Portfolios and Specifications
  13.3.3 Clinical Data, Inc. Viibryd (Vilazodone) Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Clinical Data, Inc. Main Business Overview
  13.3.5 Clinical Data, Inc. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Viibryd (Vilazodone) Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Viibryd (Vilazodone) Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of 10 mg
Table 4. Major Players of 20 mg
Table 5. Major Players of 40 mg
Table 6. Global Viibryd (Vilazodone) Sales by Type (2020-2025) & (K Units)
Table 7. Global Viibryd (Vilazodone) Sales Market Share by Type (2020-2025)
Table 8. Global Viibryd (Vilazodone) Revenue by Type (2020-2025) & ($ million)
Table 9. Global Viibryd (Vilazodone) Revenue Market Share by Type (2020-2025)
Table 10. Global Viibryd (Vilazodone) Sale Price by Type (2020-2025) & (USD/Unit)
Table 11. Global Viibryd (Vilazodone) Sale by Application (2020-2025) & (K Units)
Table 12. Global Viibryd (Vilazodone) Sale Market Share by Application (2020-2025)
Table 13. Global Viibryd (Vilazodone) Revenue by Application (2020-2025) & ($ million)
Table 14. Global Viibryd (Vilazodone) Revenue Market Share by Application (2020-2025)
Table 15. Global Viibryd (Vilazodone) Sale Price by Application (2020-2025) & (USD/Unit)
Table 16. Global Viibryd (Vilazodone) Sales by Company (2020-2025) & (K Units)
Table 17. Global Viibryd (Vilazodone) Sales Market Share by Company (2020-2025)
Table 18. Global Viibryd (Vilazodone) Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Viibryd (Vilazodone) Revenue Market Share by Company (2020-2025)
Table 20. Global Viibryd (Vilazodone) Sale Price by Company (2020-2025) & (USD/Unit)
Table 21. Key Manufacturers Viibryd (Vilazodone) Producing Area Distribution and Sales Area
Table 22. Players Viibryd (Vilazodone) Products Offered
Table 23. Viibryd (Vilazodone) Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Viibryd (Vilazodone) Sales by Geographic Region (2020-2025) & (K Units)
Table 27. Global Viibryd (Vilazodone) Sales Market Share Geographic Region (2020-2025)
Table 28. Global Viibryd (Vilazodone) Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Viibryd (Vilazodone) Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Viibryd (Vilazodone) Sales by Country/Region (2020-2025) & (K Units)
Table 31. Global Viibryd (Vilazodone) Sales Market Share by Country/Region (2020-2025)
Table 32. Global Viibryd (Vilazodone) Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Viibryd (Vilazodone) Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Viibryd (Vilazodone) Sales by Country (2020-2025) & (K Units)
Table 35. Americas Viibryd (Vilazodone) Sales Market Share by Country (2020-2025)
Table 36. Americas Viibryd (Vilazodone) Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Viibryd (Vilazodone) Sales by Type (2020-2025) & (K Units)
Table 38. Americas Viibryd (Vilazodone) Sales by Application (2020-2025) & (K Units)
Table 39. APAC Viibryd (Vilazodone) Sales by Region (2020-2025) & (K Units)
Table 40. APAC Viibryd (Vilazodone) Sales Market Share by Region (2020-2025)
Table 41. APAC Viibryd (Vilazodone) Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Viibryd (Vilazodone) Sales by Type (2020-2025) & (K Units)
Table 43. APAC Viibryd (Vilazodone) Sales by Application (2020-2025) & (K Units)
Table 44. Europe Viibryd (Vilazodone) Sales by Country (2020-2025) & (K Units)
Table 45. Europe Viibryd (Vilazodone) Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Viibryd (Vilazodone) Sales by Type (2020-2025) & (K Units)
Table 47. Europe Viibryd (Vilazodone) Sales by Application (2020-2025) & (K Units)
Table 48. Middle East & Africa Viibryd (Vilazodone) Sales by Country (2020-2025) & (K Units)
Table 49. Middle East & Africa Viibryd (Vilazodone) Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Viibryd (Vilazodone) Sales by Type (2020-2025) & (K Units)
Table 51. Middle East & Africa Viibryd (Vilazodone) Sales by Application (2020-2025) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Viibryd (Vilazodone)
Table 53. Key Market Challenges & Risks of Viibryd (Vilazodone)
Table 54. Key Industry Trends of Viibryd (Vilazodone)
Table 55. Viibryd (Vilazodone) Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Viibryd (Vilazodone) Distributors List
Table 58. Viibryd (Vilazodone) Customer List
Table 59. Global Viibryd (Vilazodone) Sales Forecast by Region (2026-2031) & (K Units)
Table 60. Global Viibryd (Vilazodone) Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Viibryd (Vilazodone) Sales Forecast by Country (2026-2031) & (K Units)
Table 62. Americas Viibryd (Vilazodone) Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Viibryd (Vilazodone) Sales Forecast by Region (2026-2031) & (K Units)
Table 64. APAC Viibryd (Vilazodone) Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Viibryd (Vilazodone) Sales Forecast by Country (2026-2031) & (K Units)
Table 66. Europe Viibryd (Vilazodone) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Viibryd (Vilazodone) Sales Forecast by Country (2026-2031) & (K Units)
Table 68. Middle East & Africa Viibryd (Vilazodone) Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Viibryd (Vilazodone) Sales Forecast by Type (2026-2031) & (K Units)
Table 70. Global Viibryd (Vilazodone) Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Viibryd (Vilazodone) Sales Forecast by Application (2026-2031) & (K Units)
Table 72. Global Viibryd (Vilazodone) Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Allergan plc (AbbVie Inc.) Basic Information, Viibryd (Vilazodone) Manufacturing Base, Sales Area and Its Competitors
Table 74. Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Product Portfolios and Specifications
Table 75. Allergan plc (AbbVie Inc.) Viibryd (Vilazodone) Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 76. Allergan plc (AbbVie Inc.) Main Business
Table 77. Allergan plc (AbbVie Inc.) Latest Developments
Table 78. Actavis Generics (Teva) Basic Information, Viibryd (Vilazodone) Manufacturing Base, Sales Area and Its Competitors
Table 79. Actavis Generics (Teva) Viibryd (Vilazodone) Product Portfolios and Specifications
Table 80. Actavis Generics (Teva) Viibryd (Vilazodone) Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Actavis Generics (Teva) Main Business
Table 82. Actavis Generics (Teva) Latest Developments
Table 83. Clinical Data, Inc. Basic Information, Viibryd (Vilazodone) Manufacturing Base, Sales Area and Its Competitors
Table 84. Clinical Data, Inc. Viibryd (Vilazodone) Product Portfolios and Specifications
Table 85. Clinical Data, Inc. Viibryd (Vilazodone) Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 86. Clinical Data, Inc. Main Business
Table 87. Clinical Data, Inc. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Viibryd (Vilazodone)
Figure 2. Viibryd (Vilazodone) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Viibryd (Vilazodone) Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Viibryd (Vilazodone) Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Viibryd (Vilazodone) Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Viibryd (Vilazodone) Sales Market Share by Country/Region (2024)
Figure 10. Viibryd (Vilazodone) Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of 10 mg
Figure 12. Product Picture of 20 mg
Figure 13. Product Picture of 40 mg
Figure 14. Global Viibryd (Vilazodone) Sales Market Share by Type in 2025
Figure 15. Global Viibryd (Vilazodone) Revenue Market Share by Type (2020-2025)
Figure 16. Viibryd (Vilazodone) Consumed in Major Depression
Figure 17. Global Viibryd (Vilazodone) Market: Major Depression (2020-2025) & (K Units)
Figure 18. Viibryd (Vilazodone) Consumed in Anxiety
Figure 19. Global Viibryd (Vilazodone) Market: Anxiety (2020-2025) & (K Units)
Figure 20. Viibryd (Vilazodone) Consumed in Others
Figure 21. Global Viibryd (Vilazodone) Market: Others (2020-2025) & (K Units)
Figure 22. Global Viibryd (Vilazodone) Sale Market Share by Application (2024)
Figure 23. Global Viibryd (Vilazodone) Revenue Market Share by Application in 2025
Figure 24. Viibryd (Vilazodone) Sales by Company in 2025 (K Units)
Figure 25. Global Viibryd (Vilazodone) Sales Market Share by Company in 2025
Figure 26. Viibryd (Vilazodone) Revenue by Company in 2025 ($ millions)
Figure 27. Global Viibryd (Vilazodone) Revenue Market Share by Company in 2025
Figure 28. Global Viibryd (Vilazodone) Sales Market Share by Geographic Region (2020-2025)
Figure 29. Global Viibryd (Vilazodone) Revenue Market Share by Geographic Region in 2025
Figure 30. Americas Viibryd (Vilazodone) Sales 2020-2025 (K Units)
Figure 31. Americas Viibryd (Vilazodone) Revenue 2020-2025 ($ millions)
Figure 32. APAC Viibryd (Vilazodone) Sales 2020-2025 (K Units)
Figure 33. APAC Viibryd (Vilazodone) Revenue 2020-2025 ($ millions)
Figure 34. Europe Viibryd (Vilazodone) Sales 2020-2025 (K Units)
Figure 35. Europe Viibryd (Vilazodone) Revenue 2020-2025 ($ millions)
Figure 36. Middle East & Africa Viibryd (Vilazodone) Sales 2020-2025 (K Units)
Figure 37. Middle East & Africa Viibryd (Vilazodone) Revenue 2020-2025 ($ millions)
Figure 38. Americas Viibryd (Vilazodone) Sales Market Share by Country in 2025
Figure 39. Americas Viibryd (Vilazodone) Revenue Market Share by Country (2020-2025)
Figure 40. Americas Viibryd (Vilazodone) Sales Market Share by Type (2020-2025)
Figure 41. Americas Viibryd (Vilazodone) Sales Market Share by Application (2020-2025)
Figure 42. United States Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 43. Canada Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 44. Mexico Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 45. Brazil Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 46. APAC Viibryd (Vilazodone) Sales Market Share by Region in 2025
Figure 47. APAC Viibryd (Vilazodone) Revenue Market Share by Region (2020-2025)
Figure 48. APAC Viibryd (Vilazodone) Sales Market Share by Type (2020-2025)
Figure 49. APAC Viibryd (Vilazodone) Sales Market Share by Application (2020-2025)
Figure 50. China Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 51. Japan Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 52. South Korea Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 53. Southeast Asia Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 54. India Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 55. Australia Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 56. China Taiwan Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 57. Europe Viibryd (Vilazodone) Sales Market Share by Country in 2025
Figure 58. Europe Viibryd (Vilazodone) Revenue Market Share by Country (2020-2025)
Figure 59. Europe Viibryd (Vilazodone) Sales Market Share by Type (2020-2025)
Figure 60. Europe Viibryd (Vilazodone) Sales Market Share by Application (2020-2025)
Figure 61. Germany Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 62. France Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 63. UK Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 64. Italy Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 65. Russia Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 66. Middle East & Africa Viibryd (Vilazodone) Sales Market Share by Country (2020-2025)
Figure 67. Middle East & Africa Viibryd (Vilazodone) Sales Market Share by Type (2020-2025)
Figure 68. Middle East & Africa Viibryd (Vilazodone) Sales Market Share by Application (2020-2025)
Figure 69. Egypt Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 70. South Africa Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 71. Israel Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 72. Turkey Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 73. GCC Countries Viibryd (Vilazodone) Revenue Growth 2020-2025 ($ millions)
Figure 74. Manufacturing Cost Structure Analysis of Viibryd (Vilazodone) in 2025
Figure 75. Manufacturing Process Analysis of Viibryd (Vilazodone)
Figure 76. Industry Chain Structure of Viibryd (Vilazodone)
Figure 77. Channels of Distribution
Figure 78. Global Viibryd (Vilazodone) Sales Market Forecast by Region (2026-2031)
Figure 79. Global Viibryd (Vilazodone) Revenue Market Share Forecast by Region (2026-2031)
Figure 80. Global Viibryd (Vilazodone) Sales Market Share Forecast by Type (2026-2031)
Figure 81. Global Viibryd (Vilazodone) Revenue Market Share Forecast by Type (2026-2031)
Figure 82. Global Viibryd (Vilazodone) Sales Market Share Forecast by Application (2026-2031)
Figure 83. Global Viibryd (Vilazodone) Revenue Market Share Forecast by Application (2026-2031)